focus -WSS

focus

author：Wikipedia 2025-09-30 17:45:46 - browse：7

This is the online edition of Adam’s Biotech Scorecard, a new subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered every Thursday to their inbox.

Hello, friends! I’m in San Francisco for the STAT Breakthrough Summit. Later today, I’ll be “fireside chatting” with Cytokinetics CEO Robert Blum. It’s not too late to join us virtually. Check out details here.

It’s a travel-shortened week for me, so in this newsletter, I decided to dive deep into PDS Biotech and its experimental drug for head and neck cancer. PDS is what I’d call a biotech cult stock.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： Wegovy leads to weight loss. Can it treat depression, too?

leisure time

WSS

Cassava reveals details — and problems — with Alzheimer's study

Testing for cancer recurrence creates a new limbo for patients

Diversifying clinical trials isn't enough to close racial gaps: study

Eli Lilly to pay $200M for Beam’s stake in gene

Emergency medicine has repudiated 'excited delirium.' Now what?

First Opinion Podcast: How to protect health care in times of war

focus

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

focus

Trump demands the U.S. pay no more for drugs than other countries … again

Diversifying clinical trials isn't enough to close racial gaps: study

Wildfire smoke exposes gaps in outdoor worker protections

STAT Wunderkinds: Ruey Hu's digital tools for parsing research

Continuity nursing helped my family in our darkest PICU moments

Cassava reveals details — and problems — with Alzheimer's study

Malaria cases in Florida and Texas: Here’s what you need to know

FTC sues over Novant Health acquisition of two N.C. hospitals

Novavax promises a turnaround & Lilly roils the obesity market

Venture capital firm's plans to take over Akron hospital face hurdles

focus

Syphilis numbers in the United States reach record heights

Biogen walks away from Aduhelm, years after polarizing approval

FTC sues over Novant Health acquisition of two N.C. hospitals

STAT Wunderkinds: Ruey Hu's digital tools for parsing research

Zyn nicotine pouches become unlikely player in latest culture war

FDA approves Eli Lilly ulcerative colitis treatment Omvoh

leisure time

knowledge

entertainment

hotspot